Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolates

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 4, 1997, Pages 831-837

  Buckheit Jr , Robert W ^a,d   Snow, Melinda J ^a   Fliakas Boltz, Valerie ^a   Kinjerski, Tracy L ^a   Russell, Julie D ^a   Pallansch, Luke A ^a   Brouwer, Walter G ^b   Yang, Stringner S ^c  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

^b Uniroyal Chemical Ltd   (Canada)

^c NATIONAL CANCER INSTITUTE   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; LAMIVUDINE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 THIOPHENECARBOTHIOAMIDE; OXATHIIN DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UC 040; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG CONFORMATION; DRUG EFFECT; DRUG POTENCY; DRUG POTENTIATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 8244226649     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.4.831     Document Type: Article

References (29)

1. Bader, J. P., J. B. McMahon, R. J. Schultz, V. L. Narayanan, J. B. Pierce, W. A. Harrison, O. S. Weislow, C. F. Midelfort, S. F. Stinson, and M. R. Boyd. 1991. Oxathiin carboxanilide, a potent inhibitor of human immunodeficiency virus reproduction. Proc. Natl. Acad. Sci. USA 88:6740-6744.
2. Balzarini, J., H. Jonckheere, W. A. Harrison, D. C. Dao, J. Anne, E. De Clercq, and A. Karlsson. 1995. Oxathiin carboxanilide derivatives: a class of nonnucleoside HIV-1-specific reverse transcriptase inhibitors (NNRTIs) that are active against mutant HIV-1 strains resistant to other NNRTIs. Antiviral Chem. Chemother. 6:169-178.
3. Boyer, P. L., M. J. Currens, J. B. McMahon, M. R. Boyd, and S. H. Hughes. 1993. Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase. J. Virol. 67:2412-2420.
4. Buckheit, R. W., Jr., M. Hollingshead, S. Stinson, V. Fliakas-Boltz, L. A. Pallansch, J. Roberson, W. Decker, C. Elder, S. Borgel, C. Bonomi, R. Shores, T. Siford, L. Malspeis, and J. P. Bader. Efficacy, pharmacokinetics and in vivo antiviral activity of UC781, a highly potent, orally bioavailable nonnucleoside reverse transcriptase inhibitor of HIV-1. AIDS Res. Hum. Retroviruses, in press.
5. Buckheit, R. W., Jr., V. Fliakas-Boltz, W. D. Decker, J. L. Roberson, C. A. Pyle, E. L. White, B. J. Bowdon, J. B. McMahon, M. R. Boyd, J. P. Bader, D. G. Nickell, H. Barth, and T. K. Antonucci. 1994. Biological and biochemical anti-HIV activity of the benzothiadiazine class of nonnucleoside reverse transcriptase inhibitors. Antiviral Res. 25:43-56.
6. Buckheit, R. W., Jr., V. Fliakas-Boltz, W. D. Decker, J. L. Roberson, T. L. Stup, C. A. Pyle, E. L. White, J. B. McMahon, M. J. Currens, M. R. Boyd, and J. P. Bader. 1995. Comparative anti-HIV evaluation of diverse HIV-1-specific reverse transcriptase inhibitor-resistant virus isolates demonstrates the existence of distinct phenotypic subgroups. Antiviral Res. 26:117-132.
7. Buckheit, R. W., Jr., J. Germany-Decker, M. G. Hollingshead, L. B. Allen, W. M. Shannon, P. A. Janssen, and M. A. Chirigos. 1993. Differential antiviral activity of two TIBO derivatives against the human immunodeficiency and murine leukemia viruses alone and in combination with other anti-HIV agents. AIDS Res. Hum. Retroviruses 9:1097-1106.
8. Buckheit, R. W., Jr., T. L. Kinjerski, V. Fliakas-Boltz, J. D. Russell, T. L. Stup, L. A. Pallansch, W. G. Brouwer, D. C. Dao, W. A. Harrison, R. J. Schultz, J. P. Bader, and S. S. Yang. 1995. Structure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type 1-specific compounds related to oxathiin carboxanilide. Antimicrob. Agents Chemother. 39:2718-2727.
9. Byrnes, V. W., V. V. Sardana, W. A. Schleif, J. H. Condra, J. A. Waterbury, J. A. Wolfgang, W. J. Long, C. L. Schneider, A. J. Schlabach, and B. S. Wolanski. 1993. Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors. Antimicrob. Agents Chemother. 37:1576-1579.
10. Clanton, D. J., R. W. Buckheit, Jr., S. J. Terpening, R. Kiser, N. Mongelli, A. L. Borgia, R. Schultz, V. Narayanan, J. P. Bader, and W. G. Rice. 1995. Novel sulfonated and phosphonated analogs of distamycin which inhibit the replication of HIV. Antiviral Res. 27:1-20.
11. Cohen, K. A., J. Hopkins, R. H. Ingraham, C. Pargellis, J. C. Wu, D. E. Palladino, P. Kinkade, T. C. Warren, S. Rogers, and J. Adams. 1991. Characterization of the binding site for nevirapine (BI-RG-587), a nonnucleoside inhibitor of human immunodeficiency virus type-1 reverse transcriptase. J. Biol. Chem. 266:14670-14674.
12. Condra, J. H., E. A. Emini, L. Gotlib, D. J. Graham, A. J. Schlabach, J. A. Wolfgang, R. J. Colonno, and V. V. Sardana. 1992. Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse nonnucleoside inhibitors. Antimicrob. Agents Chemother. 36:1441-1446.
13. Fletcher, R. S., D. Arion, G. Borkow, M. A. Wainberg, G. I. Dmitrienko, and M. A. Parniak. 1995. Synergistic inhibition of HIV-1 reverse transcriptase DNA polymerase activity and virus replication in vitro by combinations of carboxanilide non-nucleoside compounds. Biochemistry 34:10106-10112.
14. Fletcher, R. S., K. Syed, S. Mithani, G. I. Dmitrienko, and M. A. Parniak. 1995. Carboxanilide derivative non-nucleoside inhibitors of HIV-1 reverse transcriptase interact with different mechanistic forms of the enzyme. Biochemistry 34:4346-4353.
15. Grob, P. M., J. C. Wu, K. A. Cohen, R. H. Ingraham, C. K. Shin, K. D. Margrave, T. L. McTague, and V. J. Merluzzi. 1992. Nonnucleoside inhibitors of HIV-1 reverse transeriptase: nevirapine as a prototype drug. AIDS Res. Hum. Retroviruses 8:145-152.
16. Harrison, W. A., G. Jewell, E. E. Felauer, M. A. Dekeyser, D. D. Cong, J. A. McGuiness, A. Mishra, W. G. Brouwer, and D. J. McPhee. 1991. Treatment of HIV infections and compounds useful therein. Chem. Abstr. 115:904.
17. Kageyama, S., B. D. Anderson, B. L. Hoesterey, H. Hayashi, Y. Kiso, K. P. Flora, and H. Mitsuya. 1994. Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteins. Antimicrob. Agents Chemother. 38:1107-1111.
18. Kashman, Y., K. R. Gustafson, R. W. Fuller, J. H. Cardellina II, J. B. McMahon, M. J. Currens, R. W. Buckheit, Jr., S. H. Hughes, G. M. Cragg, and M. R. Boyd. 1992. The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum. J. Med. Chem. 35:2735-2743. (Erratum, 36:1110, 1996.)
19. Kinjerski, T. L., L. A. Pallansch, and R. W. Buckheit, Jr. 1996. Isolation and characterization of HIV-1 isolates resistant to oxathiin carboxanilide analogs: evaluation of variables in the resistance selection process. Antiviral Chem. Chemother. 7:261-269.
20. Klunder, J. M., K. D. Hargrave, M. West, E. Cullen, K. Pal, M. L. Behnke, S. R. Kapadia, D. W. McNeil, J. C. Wu, and G. C. Chow. 1992. Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 2. Tricyclic pyridobenzoxazepinones and dibenzoxazepinones. J. Med. Chem. 35:1887-1897.
21. Maass, G., U. Immendoerfer, B. Koenig, U. Leser, B. Mueller, R. Goody, and E. Pfaff. 1993. Viral resistance to the thiazolo-iso-indolinones, a new class of nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 37:2612-2617.
22. McMahon, J. B., R. W. Buckheit, Jr., R. J. Gulakowski, M. J. Currens, D. T. Vistica, R. H. Shoemaker, S. F. Stinson, J. D. Russell, J. P. Bader, V. L. Narayanan, R. J. Shultz, W. G. Brouwer, E. E. Felauer, and M. R. Boyd. 1995. Biological and biochemical anti-human immunodeficiency virus activity of UC-38, a new nonnucleoside reverse transcriptase inhibitor. J. Pharniacol. Exp. Ther. 276:298-305.
23. Mellors, J. W., G. E. Dutschman, G. J. Im, E. Tramontane, S. R. Winkler, and Y. C. Cheng. 1992. In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase. Mol. Pharmacol. 41:446-451. (Erratum, 42:174.)
24. Merluzzi, V. J., K. D. Hargrave, M. Labadia, K. Grozinger, M. Skoog, J. C. Wu, C. K. Shih, K. Eckner, S. Hattox, J. Adams, A. S. Roshthal, R. Faanes, R. J. Eckner, R. A. Koup, and J. L. Sullivan. 1990. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 250: 1411-1413. (Erratum, 251:362, 1991.)
25. Pauwels, R., K. Andries, J. Desmyter, D. Schols, M. J. Kukla, H. J. Breslin, A. Raeymaeckers, J. Van Gelder, R. Woestenborghs, and J. Heykants. 1990. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 343:470-474.
26. Prichard, M. N., and C. Shipman, Jr. 1990. A three-dimensional model to analyze drug-drug interactions. Antiviral Res. 14:181-206.
27. Richman, D. D., D. Havlir, J. Corbeil, D. Looney, C. Ignacio, S. A. Spector, J. Sullivan, S. Cheeseman, K. Barringer, and D. Pauletti. 1994. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 68:1660-1666.
28. Saag, M. S., E. A. Emini, O. L. Laskin, J. Douglas, W. I. Lapidus, W. A. Schleif, R. J. Whitley, C. Hildebrand, V. W. Byrnes, and J. C. Kappes. 1993. A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group. N. Engl. J. Med. 329:1065-1072.
29. Wu, J. C., T. C. Warren, J. Adams, J. Proudfoot, J. Skiles, P. Raghavan, C. Perry, I. Potocki, P. R. Farina, and P. M. Grob. 1991. A novel dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubstrate binding site. Biochemistry 30:2022-2026.